Literature DB >> 731792

Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein.

M D Lubeck, J L Schulman, P Palese.   

Abstract

Influenza A virus recombinants derived from "resistant" and "sensitive" parental viruses were examined for susceptibility to inhibition by amantadine. Correlation of gene constellation and amantadine susceptibility revealed that the gene coding for M protein influences sensitivity or resistance to amantadine. All recombinants which derived an M protein from an amantadine-resistant parent were found to be resistant to amantadine. All amantadine-sensitive recombinants derived an M gene from the amantadine-sensitive parent. However, a few amantadine-resistant recombinants which derived an M gene from the sensitive parent were also isolated, suggesting that the expression of amantadine sensitivity in these recombinants may be influenced by other genes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 731792      PMCID: PMC525794     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  17 in total

1.  Effect of adamantane derivatives on the activity of orthomyxovirus RNA-dependent RNA polymerase.

Authors:  V A Kalninya; M K Indulen
Journal:  Acta Virol       Date:  1976-08       Impact factor: 1.162

2.  Mode of Action of the Antiviral Activity of Amantadine in Tissue Culture.

Authors:  C E Hoffmann; E M Neumayer; R F Haff; R A Goldsby
Journal:  J Bacteriol       Date:  1965-09       Impact factor: 3.490

3.  Mapping of the influenza virus genome. II. Identification of the P1, P2, and P3 genes.

Authors:  P Palese; M B Ritchey; J L Schulman
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

4.  A single gene determines the host range of influenza virus.

Authors:  J W Almond
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

5.  THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES.

Authors:  R R GRUNERT; J W MCGAHEN; W L DAVIES
Journal:  Virology       Date:  1965-06       Impact factor: 3.616

6.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

7.  Mapping of the influenza virus genome. III. Identification of genes coding for nucleoprotein, membrane protein, and nonstructural protein.

Authors:  M B Ritchey; P Palese; J L Schulman
Journal:  J Virol       Date:  1976-10       Impact factor: 5.103

8.  Mapping of the influenza virus genome: identification of the hemagglutinin and the neuraminidase genes.

Authors:  P Palese; J L Schulman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-06       Impact factor: 11.205

9.  Virulence factors of influenza A viruses: WSN virus neuraminidase required for plaque production in MDBK cells.

Authors:  J L Schulman; P Palese
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

10.  On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride.

Authors:  J J Skehel; A J Hay; J A Armstrong
Journal:  J Gen Virol       Date:  1978-01       Impact factor: 3.891

View more
  26 in total

Review 1.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

2.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein.

Authors:  S L Zebedee; R A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Influenza virus strains with a fusion threshold of pH 5.5 or lower are inhibited by amantadine. Brief report.

Authors:  W E Beyer; R W Ruigrok; H van Driel; N Masurel
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

5.  Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection.

Authors:  R B Belshe; M H Smith; C B Hall; R Betts; A J Hay
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

6.  Rimantadine hydrochloride blocks the second step of influenza virus uncoating.

Authors:  A G Bukrinskaya; N K Vorkunova; R A Narmanbetova
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

7.  Enhancement of activity against influenza viruses by combinations of antiviral agents.

Authors:  F G Hayden; R G Douglas; R Simons
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

8.  Inhibition of influenza A virus replication by compounds interfering with the fusogenic function of the viral hemagglutinin.

Authors:  S J Plotch; B O'Hara; J Morin; O Palant; J LaRocque; J D Bloom; S A Lang; M J DiGrandi; M Bradley; R Nilakantan; Y Gluzman
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  The amantadine-sensitivity of recombinant and parental influenza virus strains.

Authors:  M Hamzawi; R Jennings; C W Potter
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

10.  Nucleotide sequence of the gene encoding respiratory syncytial virus matrix protein.

Authors:  M Satake; S Venkatesan
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.